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Unfaithful proteins no problem for DNA repair
D
NA repair pro-
teins constant-
ly bind and let 
go of DNA damage 
sites. Luijsterburg et 
al. discover how these 
seemingly fickle pro-
teins get the job done.
During nucleotide 
excision repair, ten proteins collaborate to fi  x DNA, handling 
separate steps such as recognizing damage, unwinding the DNA, 
snipping out the marred section, and installing replacement 
nucleotides. Instead of assembling into a complex beforehand, 
the proteins come together at the site of damage. So how do the 
proteins make repairs if they adhere to the complex only for 
a short time?
Luijsterburg et al. tracked seven of the proteins in cells zapped 
by ultraviolet light. Repair complexes stuck to DNA for hours, 
but individual proteins only adhered for tens of seconds. This 
isn’t contradictory, the researchers say. Proteins randomly attach 
and detach until the right combination is present to catalyze the 
fi  rst repair step. Reshuffl  ing continues until a complex convenes 
to catalyze the next step, and so on. The result challenges previous 
fi  ndings that complexes assemble in sequence, with each protein 
staying on after its task is complete.
Luijsterburg et al.’s model suggests a benefi  t for quick-release 
proteins. They make it easier to abort the process if repair starts 
on undamaged DNA, a mistake that can result in mutations. 
Next up, the researchers say, is determining whether similar 
mechanisms occur in other processes involving unstable complexes, 
such as DNA replication and transcription.
Luijsterburg, M.S., et al. 2010. J. Cell Biol. doi:10.1083/jcb.200909175.
Skeleton key for metastasis
C
ancer cells 
need all three 
of their cy-
toskeletons—actin, mi-
crotubules, and interme-
diate fi  laments—to me-
tastasize,  Schoumacher 
et al. reveal.
A cancer cell in an epithelial layer is trapped unless it can 
force through the basement membrane, which cordons off the 
tissue. Tumor cells start to dissolve the basement membrane with 
enzymes that build up within extensions called invadopodia. 
How the different components of the cytoskeleton collaborate to 
spring the cell remains unclear. To fi   nd out, the researchers 
followed cancer cells as they started their breakout.
Schoumacher et al. found that a tumor cell escapes in three stages. 
First, stumpy protrusions dig into the basement membrane. These 
structures then elongate into “mature” invadopodia. Finally, the 
rest of the cell follows. In culture, crawling cells produce extensions 
that carry either bundles of actin or an actin mesh. In the cancer 
cells, both forms of actin were necessary for invadopodia to form 
and grow. However, microtubules and intermediate fi  laments were 
only essential for invadopodia to lengthen.
The researchers suggest a model for this initial step of 
metastasis. Growing actin bundles push out a protrusion, 
which the actin mesh stabilizes as it elongates. Only if the 
invadopodium stretches beyond 5 μm do microtubules and 
intermediate fi  laments get involved. Microtubules most likely 
elongate the invadopodium by delivering materials such as 
enzymes to the tip. Intermediate fi  laments, meanwhile, may 
brace the growing extension.
Schoumacher, M., et al. 2010. J. Cell Biol. doi:10.1083/jcb.200909113.
An actin-rich invadopodium pushes through 
the basement membrane (red, left), allowing 
the tumor cell to follow (right).
RALT doubles down on EGFR
F
rosi et al. de-
scribe a new 
mechanism for 
turning down epidermal 
growth factor receptor 
(EGFR) activity that 
dispatches the protein 
for destruction.
Through its kinase 
activity, EGFR is cru-
cial for cell division, 
survival, and movement. But faulty or overactive EGFR abets 
many cancers. Several cellular controls keep EGFR in check. 
After the receptors are stimulated, for example, endocytosis 
abducts them from the cell surface. Alternatively, a protein called 
RALT blocks EGFR’s activity by clamping onto its kinase 
domain. But RALT sometimes follows internalized receptors 
into the cell, an unexpected behavior because kinase activity is 
necessary for EGFR endocytosis. Frosi et al. wondered whether 
RALT could suppress EGFR yet drive its endocytosis.
The researchers discovered that RALT can trigger the 
receptor’s endocytosis by maneuvering it into clathrin-coated 
pits. To move the receptor into position, RALT connects to two 
kinds of proteins—AP-2 and the intersectins—that transfer 
molecules into the pits and allow their maturation into vesicles.
RALT directs EGFR to the lysosomes for digestion. Proteins 
destined for destruction often carry ubiquitin tags, but the researchers 
showed that EGFR ubiquitylation wasn’t required when RALT was 
involved. Thus to rapidly decrease EGFR signaling, RALT blocks 
the receptor’s kinase activity. For a slower, longer-lasting effect, it 
also promotes the molecule’s removal and destruction. A key 
question is RALT’s role in cancer—a recent study pegged it as a 
tumor suppressor in the brain cancer glioblastoma.
Frosi, Y., et al. 2010. J. Cell Biol. doi:10.1083/jcb.201002032.
XPA (green), a protein that helps snip out 
DNA lesions, accumulates early in the 
repair process, as this time series shows.
RALT ushers endocytosed EGFR (red) to 
lysosomes (green) for destruction.